Recent advances in the management of pulmonary sarcomatoid carcinoma.

about

Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.

P2860

Q38748140-E4F5B30D-F21F-4B2A-BE20-6AF70ACB1AA3

P2860

Recent advances in the management of pulmonary sarcomatoid carcinoma.

Item

http://www.wikidata.org/entity/Q52881354

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@en

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@nl

type

Item

label

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@en

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@nl

prefLabel

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@en

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@nl

P1476

Recent advances in the management of pulmonary sarcomatoid carcinoma.

@en

P2093

Alain Borczuk

http://www.w3.org/2001/XMLSchema#string

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Elaine Shum

http://www.w3.org/2001/XMLSchema#string

Feng Wang

http://www.w3.org/2001/XMLSchema#string

Haiying Cheng

http://www.w3.org/2001/XMLSchema#string

Matthew Stuart

http://www.w3.org/2001/XMLSchema#string

P2860

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Pulmonary giant cell carcinoma: pathological entity or morphological phenotype?

Carcinosarcomas of the lung: a clinicopathologic study of 66 patients.

Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung.

Palliative chemotherapy for pulmonary pleomorphic carcinoma.

Sarcomatoid carcinoma of the lung: a predictor of poor prognosis.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17476348.2016.1157475

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26962707

http://www.w3.org/2001/XMLSchema#string

Recent advances in the management of pulmonary sarcomatoid carcinoma.

about

P2860

P2860

Recent advances in the management of pulmonary sarcomatoid carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698